ERVW-1 and AIDS: An effective prophylactic AIDS vaccine will need to generate anti-HIV neutralizing antibodies (Abs) that target the HIV envelope glycoprotein (Env) [1]–[3] and broadly neutralize as many HIV isolates as possible (bNAbs).